

# Portugal meningococcal B vaccine (menB) effectiveness study

<b>Submission date</b> 15/05/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 21/05/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 02/12/2020	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Meningococcal group B bacteria are a serious cause of life-threatening infections worldwide, including meningitis and blood poisoning. Developing a vaccine against the most common cause (type B) has been a priority but technically very difficult. Because the disease is so rare it has not been possible to carry out the standard type of study (randomised controlled trial) to prove that these vaccines actually protect people against the disease, instead licensure was based on the pattern of antibodies produced and predicted coverage of the commonest strains of Meningococcal disease.

### Who can participate?

All children and adolescents diagnosed with invasive meningococcal disease in Portugal between October 2014 and March 2019 inclusive will be eligible for inclusion. For each case, 2 - 4 age and location matched controls will be identified.

### What does the study involve?

Examination of medical records including immunisation history of cases and matched controls

### What are the possible benefits and risks of participating?

None

### Where is the study run from?

Coimbra, Portugal with participation of multiple hospitals in Portugal

### When is the study starting and how long is it expected to run for?

April 2018 to September 2019

### Who is funding the study?

The investigators and clinicians providing data are undertaking the study as part of their professional duties. No external funding has been sought or obtained.

### Who is the main contact?

1. Dr Robin Marlow,

robin.marlow@bristol.ac.uk  
2. Prof. Fernanda Rodrigues,  
rodriguesfmp@gmail.com  
3. Prof. Adam Finn,  
adam.finn@bristol.ac.uk

## Contact information

### Type(s)

Scientific

### Contact name

Dr Robin Marlow

### ORCID ID

<https://orcid.org/0000-0002-3192-3102>

### Contact details

Level 6  
BRI Education Centre  
Bristol  
United Kingdom  
BS2 8AE  
0117 342 0172  
robin.marlow@bristol.ac.uk

### Type(s)

Scientific

### Contact name

Prof Fernanda Rodrigues

### ORCID ID

<https://orcid.org/0000-0002-5820-5215>

### Contact details

Centro Hospitalar e Universitário de Coimbra - Hospital Pediátrico  
Coimbra  
Portugal  
3000-602  
+351 239 488 700  
frodrigues@chc.min-saude.pt

### Type(s)

Scientific

### Contact name

Prof Adam Finn

### ORCID ID

<https://orcid.org/0000-0003-1756-5668>

### **Contact details**

Level 6  
BRI Education Centre  
Bristol  
United Kingdom  
BS2 8AE  
0117 342 0172  
adam.finn@bristol.ac.uk

## **Additional identifiers**

### **Clinical Trials Information System (CTIS)**

Nil known

### **ClinicalTrials.gov (NCT)**

Nil known

### **Protocol serial number**

1.3

## **Study information**

### **Scientific Title**

Case control study to evaluate the effectiveness of the 4CMenB vaccine for protection against invasive meningococcal disease caused by group B *Neisseria meningitidis* in Portugal

### **Acronym**

PT-BEST

### **Study objectives**

Current study hypothesis as of 03/07/2019:

That rates of full immunisation per licensed schedule for age with Bexsero among children presenting with culture and/or PCR-proven meningococcus group B invasive disease will be significantly lower than among age and gender-matched controls presenting at the same hospitals at around the same time with conditions unrelated to meningococcal infection.

Previous study hypothesis:

That rates of full immunisation per licensed schedule for age with Bexsero will be significantly higher among children presenting with culture and/or PCR-proven meningococcus group B invasive disease will be significantly lower than among age and gender-matched controls presenting at the same hospitals at around the same time with conditions unrelated to meningococcal infection.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 14/05/2018, Ethics Committee from Centro Hospitalar e Universitário de Coimbra (Centro Hospitalar Universitário de Coimbra, Serviço de Doenças Infecciosas, Praceta Mota Pinto, 3000-075 Coimbra, Portugal; +351 239 400 402; jscunha@fmed.uc.pt), ref: CHUC-099-17 National Data Protection authorisation number 306/ 2018

## **Study design**

Multi-centre density case-control study

## **Primary study design**

Observational

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Neisseria meningitidis

## **Interventions**

All children and adolescents diagnosed with invasive meningococcal disease in Portugal between October 2014 and March 2019 inclusive will be eligible for inclusion. For each case, 2-4 age and location matched controls will be identified.

The study involves examination of medical records and extraction of anonymised information.

## **Intervention Type**

Biological/Vaccine

## **Phase**

Phase IV

## **Drug/device/biological/vaccine name(s)**

4CMenB (Bexsero®)

## **Primary outcome(s)**

Effectiveness of the 4CMenB vaccine for protection against invasive meningococcal disease caused by group B Nm in Portugal (partially immunized children considered unvaccinated). Data are extracted from the medical records of cases and matched controls including immunisation history.

## **Key secondary outcome(s)**

1. Effectiveness of the 4CMenB vaccine for protection against invasive meningococcal disease caused by group B Nm in Portugal when partially vaccinated children are excluded from analysis.
  2. Effectiveness of one or more doses of 4CMenB vaccine for protection against invasive meningococcal disease caused by group B Nm in Portugal (i.e. partially vaccinated children included in analysis but considered to be vaccinated).
  3. Effectiveness of the 4CMenB vaccine, using the 3 approaches summarized above, for protection against all-cause invasive meningococcal disease in Portugal.
- Standardised data are extracted from the medical records of cases and matched controls including immunisation history.

## Completion date

01/09/2019

# Eligibility

## Key inclusion criteria

Case participant inclusion criteria:

1. Age > 2 months and 14 days and < 18 years
2. Meningococcal invasive disease confirmed by culture or PCR in a normally-sterile biological sample (blood, CSF, pleural fluid, joint fluid, other)
3. Resident in Portugal at time of presentation
4. Eligible to have received and responded to 4CMenB (age at least 2 months and 14 days, absence of vaccine contraindication)
5. Available information about vaccine status for 4CMenB, MenC and MenACWY from central immunisation records database.

Control participant inclusion criteria:

6. Born within specified time period of matched case participant. If case is less than < 2 years old, controls have to have been born +/- 14 days (minimum age of 2 months and 14 days); if cases are aged 2-5 years, controls have to have been born +/- 60 days, if cases are aged >= 5 years or more, controls have to have been born +/-90 days
7. Eligible to have received and responded to 4CMenB (aged at least  $\geq$  2 months and 14 days, absence of vaccine contraindication)
8. Living in the same district as the case
9. Same gender as the case
10. Presenting to the same hospital, within the same week of the case (up to 14 days before or after the day when the case was observed), with an illness that was clearly not invasive meningococcal disease (i.e. not meningitis, septicaemia or pyrexia of unknown origin)
11. Available information about vaccine status for 4CMenB, MenC and MenACWY from central immunisation records database

Vaccination status:

For the primary analysis, children who have received the appropriate number of vaccine doses for their age will be considered vaccinated – i.e. those aged 4 to 15 months who have had 2 or more vaccine doses with the second dose at least 14 days before presentation and those aged 16 months or more who have had either 2 or 3 doses before 1 year of age and one dose after 1 year of age (with the booster dose at least 14 days before presentation) or who have had at least 2 vaccine doses after the first birthday (with the second dose at least 14 days before presentation). All children who have received fewer than the appropriate number of doses as defined above will be considered unvaccinated. Children too young to have received two priming doses with the second at least 14 days before presentation (i.e. less than 4 months and 14 days old) will not be included in this analysis.

## Participant type(s)

Mixed

## Healthy volunteers allowed

No

## Age group

Child

**Lower age limit**

2 months

**Upper age limit**

18 years

**Sex**

All

**Total final enrolment**

98

**Key exclusion criteria**

1. Unknown vaccine status from centralised immunisation records database
2. Belonging to a risk group for meningococcal invasive disease: asplenia, immunodeficiency including but not restricted to complement deficiency or on treatment with Eculizumab
3. History of invasive meningococcal disease
4. Recent known or suspected contact with a case of meningococcal invasive disease

**Date of first enrolment**

01/04/2019

**Date of final enrolment**

01/09/2019

**Locations****Countries of recruitment**

Portugal

**Study participating centre**

**Hospital Pediátrico - Centro Hospitalar e Universitário de Coimbra**

Av. Afonso Romão

Coimbra

Portugal

3000-602

**Study participating centre**

**Centro Materno Infantil do Norte**

Largo da Maternidade de Júlio Dinis

Porto

Portugal

4050-651

**Study participating centre**

**Hospital S. Pedro - Centro Hospitalar Trás-os-Montes e Alto Douro**

R. dos Lagoeiros 43

Vila Real

Portugal

5000-508

**Study participating centre**

**Centro Hospitalar da Póvoa do Varzim/Vila do Conde**

Largo da Misericórdia

Póvoa do Varzim

Portugal

4490-421

**Study participating centre**

**Centro Hospitalar de Vila Nova de Gaia**

Rua Conceição Fernandes, s/n

Vila Nova de Gaia

Portugal

4434-502

**Study participating centre**

**Centro Hospitalar Barreiro Montijo**

Av. Movimento das Forças Armadas 79C

Barreiro

Portugal

2830-003

**Study participating centre**

**Centro Hospitalar de S. João**

Alameda Prof. Hernâni Monteiro

Porto

Portugal

4200-319

**Study participating centre**

**Hospital de Faro - Centro Hospitalar do Algarve**

R. Leão Penedo

Faro

Portugal

8000-386

**Study participating centre**  
**Hospital de Aveiro - Centro Hospitalar do Baixo Vouga**  
Avenida Doutor Artur Ravara  
Aveiro  
Portugal  
3810-193

**Study participating centre**  
**Hospital D. Estefânia - Centro Hospitalar Lisboa Central**  
R. Jacinta Marto  
Lisboa  
Portugal  
1169-045

**Study participating centre**  
**H. Santa Maria - Centro Hospitalar Lisboa Norte**  
Av. Prof. Egas Moniz  
Lisboa  
Portugal  
1649-035

**Study participating centre**  
**Hospital Padre Américo - Centro Hospitalar Tâmega e Sousa**  
Avenida do Hospital Padre Américo 210  
Penafiel  
Portugal  
4564-007

**Study participating centre**  
**Centro Hospitalar da Cova da Beira**  
Quinta do Alvito  
Covilhã  
Portugal  
6200-251

**Study participating centre**  
**Hospital de Torres Novas - Centro Hospitalar do Médio Tejo**  
R. Xanana Gusmão, 45

Torres Novas  
Portugal  
2350-754

**Study participating centre**  
**Hospital Beatriz Angelo**  
Av. Carlos Teixeira, 514  
Loures  
Portugal  
3 2674-514

**Study participating centre**  
**Hospital Cuf Descobertas**  
R. Mário Botas  
Lisboa  
Portugal  
1998-018

**Study participating centre**  
**Hospital CUF Porto**  
Estrada da Circunvalação, 14341  
Porto  
Portugal  
4100-180

**Study participating centre**  
**Hospital de Braga**  
Sete Fontes - São Victor  
Braga  
Portugal  
4710-243

**Study participating centre**  
**Hospital de Cascais**  
Av. Brigadeiro Victor Novais Gonçalves  
Cascais  
Portugal  
2755-009

**Study participating centre**  
**Hospital de S. Teotónio - Centro Hospitalar Tondela Viseu**  
Av. Rei Dom Duarte  
Viseu  
Portugal  
3504-509

**Study participating centre**  
**Hospital de Santarém**  
Av. Bernardo Santareno, 3737B  
Santarém  
Portugal  
2005-177Hospital de Santo Espírito

**Study participating centre**  
**Hospital de Santo Espírito**  
Canada do Briado  
Terceira  
Portugal  
9700-049

**Study participating centre**  
**Hospital do Divino Espírito Santo**  
Av. D. Manuel I - Matriz  
Ponta Delgada  
Portugal  
9500-370

**Study participating centre**  
**Hospital Espírito Santo**  
Largo do Sr. da Pobreza  
Évora  
Portugal  
7000-811

**Study participating centre**  
**Hospital Fernando da Fonseca**  
IC 19  
Amadora  
Portugal  
2720-276

**Study participating centre**

**Hospital Garcia de Orta**

Av. Torrado da Silva

Almada

Portugal

2805-267

**Study participating centre**

**Hospital S. Bernardo**

R. Camilo Castelo Branco 175

Setúbal

Portugal

2910-549

**Study participating centre**

**Hospital Senhora da Oliveira**

R. dos Cutileiros 114, Creixomil

Guimarães

Portugal

4835-044

**Study participating centre**

**ULS Baixo Alentejo - Hospital de Beja**

R. Dr. Antonio Fernando Covas Lima

Beja

Portugal

7801-849

**Study participating centre**

**Unidade Local de Saúde Alto Minho - Hospital de S. Luzia**

Estr. de Santa Luzia 50

Viana do Castelo

Portugal

4901-858

**Study participating centre**

**Hospital de S. André - Centro Hospitalar de Leiria**

R. de Santo André

Leiria  
Portugal  
2410-197

**Study participating centre**  
**Hospital Privado Algarve**  
Urbanização Casal de Gambelas  
Faro  
Portugal  
8005-226

**Study participating centre**  
**Hospital Nélio Mendonça**  
Av. Luís de Camões 6180  
Funchal  
Portugal  
9000-177

## Sponsor information

**Organisation**  
Sociedade Portuguesa de Pediatria

## Funder(s)

**Funder type**  
Other

**Funder Name**  
Investigator initiated and funded.

## Results and Publications

**Individual participant data (IPD) sharing plan**  
The datasets generated during and/or analysed during the current study will be stored in a publically available repository  
University of Bristol Research Data Repository  
data.bris

<https://www.bristol.ac.uk/staff/researchers/data/accessing-research-data/>  
Anonymised dataset used to calculate effectiveness (both primary and secondary endpoints) including age in months, date of presentation and immunisation history of cases and controls. Data will become available when study is published and will be available indefinitely. Data will be open access and users will be able to download and analyse it in whatever way they wish.

This study was a case-control study involving access to personally identifiable information only by managing clinical teams and no identifiers were provided to researchers running the study and undertaking the analysis.

It was not feasible nor deemed necessary by the ethical committee and data protection regulators to obtain consent from cases or controls.

There are no ethical or legal restrictions.

## IPD sharing plan summary

Stored in repository

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/12/2020	02/12/2020	Yes	No